These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
983 related articles for article (PubMed ID: 17459461)
1. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients. Li J; Yang W; Wu X Gynecol Oncol; 2007 Jun; 105(3):769-75. PubMed ID: 17459461 [TBL] [Abstract][Full Text] [Related]
2. Outcome and prognostic factors in ovarian germ cell malignancies. Lai CH; Chang TC; Hsueh S; Wu TI; Chao A; Chou HH; Wang PN Gynecol Oncol; 2005 Mar; 96(3):784-91. PubMed ID: 15721426 [TBL] [Abstract][Full Text] [Related]
4. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study. Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834 [TBL] [Abstract][Full Text] [Related]
5. Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors. Cicin I; Saip P; Guney N; Eralp Y; Ayan I; Kebudi R; Topuz E Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):210-4. PubMed ID: 19419810 [TBL] [Abstract][Full Text] [Related]
6. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers. Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879 [TBL] [Abstract][Full Text] [Related]
7. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy. Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521 [TBL] [Abstract][Full Text] [Related]
8. [Treatment outcome of children and adolescents with germ cell tumor after combined therapy---a report of 44 cases]. Sun XF; Yang QY; Zhen ZJ; Xia Y; Huang ZH; Ling JY Ai Zheng; 2006 Dec; 25(12):1529-32. PubMed ID: 17166380 [TBL] [Abstract][Full Text] [Related]
9. [Comprehensive staging surgery in treatment of malignant ovarian germ cell tumor]. Jin Y; Pan LY; Huang HF; Shen K; Wu M; Yang JX; Lang JH Zhonghua Fu Chan Ke Za Zhi; 2005 Dec; 40(12):826-30. PubMed ID: 16412329 [TBL] [Abstract][Full Text] [Related]
10. [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study]. Göbel U; Bamberg M; Engert J; Gnekow AK; Haas HJ; Jürgens H; Kühl J; Lenard HG; Lumenta C; Niethammer D Klin Padiatr; 1991; 203(4):236-45. PubMed ID: 1719267 [TBL] [Abstract][Full Text] [Related]
12. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Kang H; Kim TJ; Kim WY; Choi CH; Lee JW; Kim BG; Bae DS Gynecol Oncol; 2008 Oct; 111(1):106-10. PubMed ID: 18656249 [TBL] [Abstract][Full Text] [Related]
13. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126 [TBL] [Abstract][Full Text] [Related]
14. [BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89]. Göbel U; Calaminus G; Teske C; Bamberg M; Bökkerink JP; Haas RJ; Holschneider AM; Janka-Schaub G; Jürgens H; Mittler U Klin Padiatr; 1993; 205(4):231-40. PubMed ID: 7690864 [TBL] [Abstract][Full Text] [Related]
15. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. Dimopoulos MA; Papadopoulou M; Andreopoulou E; Papadimitriou C; Pavlidis N; Aravantinos G; Aspropotamitis A; Anagnostopoulos A; Fountzilas G; Michalas S; Pectacides D Gynecol Oncol; 1998 Jul; 70(1):70-4. PubMed ID: 9698477 [TBL] [Abstract][Full Text] [Related]
16. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096 [TBL] [Abstract][Full Text] [Related]
17. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603 [TBL] [Abstract][Full Text] [Related]
18. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. Kesler KA; Rieger KM; Hammoud ZT; Kruter LE; Perkins SM; Turrentine MW; Schneider BP; Einhorn LH; Brown JW Ann Thorac Surg; 2008 Feb; 85(2):371-8. PubMed ID: 18222228 [TBL] [Abstract][Full Text] [Related]
19. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma. McCreath WA; Eisenhauer EL; Abu-Rustum NR; Venkatraman ES; Caceres A; Bier R; Huh J; Cho J; Barakat RR; Chi DS Gynecol Oncol; 2006 Jul; 102(1):8-14. PubMed ID: 16427689 [TBL] [Abstract][Full Text] [Related]
20. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC). Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]